6 Segment information

	Life Sciences Business		Partnering Business		Corporate/consolidation		Group
	2020	2021	2020	2021	2020	2021	2020	2021
CHF 1,000
Sales third	408,792	485,061	322,087	461,562	–	-	730,879	946,623
Intersegment sales	40,534	35,461	1,599	1,492	(42,133)	(36,953)	–	-

Total sales	449,326	520,522	323,686	463,054	(42,133)	(36,953)	730,879	946,623

Operating profit	78,203	103,743	59,102	59,247	(15,915)	(17,473)	121,390	145,517

Depreciation and amortization	(23,501)	(22,850)	(12,164)	(36,194)	–	-	(35,665)	(59,044)
Impairment losses	(2,051)	-	–	-	–	-	(2,051)	-

	2020	2021
CHF 1,000
Reconciliation of reportable segment sales
Total sales for reportable segments	773,012	983,576
Elimination of intersegment sales	(42,133)	(36,953)
Total consolidated sales	730,879	946,623

Reconciliation of reportable segment profit
Total operating profit for reportable segments	137,305	162,990
Unallocated costs (business development, investor relations and other corporate costs) and consolidation entries	(15,915)	(17,473)
Financial result	(3,163)	(7,592)
Total consolidated profit before taxes	118, 227	137,925

	Property, plant and equipment		Right-of-use assets		Intangible assets
	31.12.2020	31.12.2021	31.12.2020	31.12.2021	31.12.2020	31.12.2021
CHF 1,000
Switzerland	17,473	17,877	19,865	16,370	104,275	101,780
Other Europe	5,338	5,335	5,609	10,667	6,607	5,457
USA	17,387	40,651	8,820	33,229	103,026	976,823
Asia	1,941	23,924	2,788	2,280	–	53,709

Total	42,139	87,787	37,082	62,546	213,908	1,137,769

There were no sales to one individual customer that in aggregate exceeded 10% of total sales in 2020 and 2021.